InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
2.430
-0.010 (-0.41%)
Jul 30, 2025, 4:00 PM - Market closed
InspireMD Revenue
InspireMD had revenue of $1.53M in the quarter ending March 31, 2025, with 1.19% growth. This brings the company's revenue in the last twelve months to $7.03M, up 8.49% year-over-year. In the year 2024, InspireMD had annual revenue of $7.01M with 12.96% growth.
Revenue (ttm)
$7.03M
Revenue Growth
+8.49%
P/S Ratio
15.93
Revenue / Employee
$81,709
Employees
86
Market Cap
74.14M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.01M | 804.00K | 12.96% |
Dec 31, 2023 | 6.21M | 1.03M | 20.00% |
Dec 31, 2022 | 5.17M | 676.00K | 15.04% |
Dec 31, 2021 | 4.50M | 2.01M | 80.89% |
Dec 31, 2020 | 2.49M | -1.24M | -33.22% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NSPR News
- 8 days ago - InspireMD to Announce Second Quarter 2025 Financial Results - GlobeNewsWire
- 21 days ago - InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke - GlobeNewsWire
- 5 weeks ago - InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke - GlobeNewsWire
- 6 weeks ago - InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke - GlobeNewsWire
- 2 months ago - InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer - GlobeNewsWire
- 2 months ago - InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - InspireMD Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference - GlobeNewsWire